Over $20 Million Carved Out From Statistical, Operations enters 2

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI: NCTN Makes “Amazing Trials” Possible

“It is important to note that the $151 million does not capture the many other functions that NCI provides in support of the NCTN and the entire clinical trials enterprise,” Garrett said. “A few of these key centralized functions include the Cancer Trials Support Unit (CTSU), a ‘one-stop shop’ for the groups to access all trials, a Central Institutional Review Board (CIRB) to eliminate the need for local IRB approvals, tumor banking for each group, and ancillary studies funded to support biomarker and quality of life research.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

In this week's episode of The Cancer Letter Podcast, editor and publisher Paul Goldberg, and associate editor Jacquelyn Cobb revisit two of last week’s most-read stories: the growing recognition that early-onset colorectal cancer requires a new diagnostic mindset, and the life and legacy of Maura Gillison, the scientist whose discovery that most head and neck cancers are driven by HPV transformed the field. 
For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login